Lemaitre Vascular (LMAT) EBITDA (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of EBITDA data on file, last reported at $17.8 million in Q1 2026.

• On a quarterly basis, EBITDA rose 40.78% year-over-year to $17.8 million in Q1 2026; TTM through Mar 2026 was $73.1 million, a 37.83% increase from a year earlier, with the FY2025 full-year figure at $67.9 million, up 29.96% from the prior year.
• EBITDA for Q1 2026 stood at $17.8 million, down from $18.8 million in the prior quarter.
• Over the last five years, EBITDA for LMAT reached as high as $20.3 million in Q3 2025 and fell as low as $5.8 million in Q2 2022.
• Historically, EBITDA has averaged $11.9 million across 5 years, with a median of $11.9 million in 2024.
• Across the five-year window, EBITDA tumbled 47.92% in 2022 and jumped 63.42% in 2023, its largest moves.
• Year by year, EBITDA stood at $7.0 million in 2022, then soared by 46.49% to $10.2 million in 2023, then gained by 25.95% to $12.9 million in 2024, then surged by 46.51% to $18.8 million in 2025, then slipped by 5.61% to $17.8 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $17.8 million in Q1 2026, $18.8 million in Q4 2025, and $20.3 million in Q3 2025.